New drug cocktail shows promise for BRCA breast cancer
NCT ID NCT03685331
First seen Nov 21, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This early-phase study tested a combination of three drugs (olaparib, palbociclib, and fulvestrant) in 9 people with a specific type of advanced breast cancer linked to BRCA gene mutations. The main goal was to check if the combination is safe and to see how long it keeps the cancer from growing. Participants had hormone receptor-positive, HER2-negative cancer that had spread or couldn't be removed by surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.